JP2004532839A5 - - Google Patents

Download PDF

Info

Publication number
JP2004532839A5
JP2004532839A5 JP2002577925A JP2002577925A JP2004532839A5 JP 2004532839 A5 JP2004532839 A5 JP 2004532839A5 JP 2002577925 A JP2002577925 A JP 2002577925A JP 2002577925 A JP2002577925 A JP 2002577925A JP 2004532839 A5 JP2004532839 A5 JP 2004532839A5
Authority
JP
Japan
Prior art keywords
mif
polypeptide
mammal
fragment
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002577925A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004532839A (ja
JP4202763B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/009580 external-priority patent/WO2002079517A1/en
Publication of JP2004532839A publication Critical patent/JP2004532839A/ja
Publication of JP2004532839A5 publication Critical patent/JP2004532839A5/ja
Application granted granted Critical
Publication of JP4202763B2 publication Critical patent/JP4202763B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002577925A 2001-03-29 2002-03-29 マクロファージ遊走阻止因子レセプターとしてのｍｈｃクラスｉｉ不変鎖ポリペプチド使用のための方法及び組成物 Expired - Fee Related JP4202763B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27943501P 2001-03-29 2001-03-29
PCT/US2002/009580 WO2002079517A1 (en) 2001-03-29 2002-03-29 Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor

Publications (3)

Publication Number Publication Date
JP2004532839A JP2004532839A (ja) 2004-10-28
JP2004532839A5 true JP2004532839A5 (enExample) 2005-12-22
JP4202763B2 JP4202763B2 (ja) 2008-12-24

Family

ID=23068959

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002577925A Expired - Fee Related JP4202763B2 (ja) 2001-03-29 2002-03-29 マクロファージ遊走阻止因子レセプターとしてのｍｈｃクラスｉｉ不変鎖ポリペプチド使用のための方法及び組成物

Country Status (10)

Country Link
US (10) US20030013122A1 (enExample)
EP (1) EP1383919B1 (enExample)
JP (1) JP4202763B2 (enExample)
AT (1) ATE473294T1 (enExample)
AU (1) AU2002255961B2 (enExample)
CA (1) CA2455915C (enExample)
DE (1) DE60236921D1 (enExample)
DK (1) DK1383919T3 (enExample)
ES (1) ES2352228T3 (enExample)
WO (1) WO2002079517A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4202763B2 (ja) * 2001-03-29 2008-12-24 サイトカイン・ファーマサイエンシズ・インコーポレーテッド マクロファージ遊走阻止因子レセプターとしてのｍｈｃクラスｉｉ不変鎖ポリペプチド使用のための方法及び組成物
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
KR101017732B1 (ko) * 2002-03-01 2011-02-28 이뮤노메딕스, 인코오포레이티드 내재화 항-ｃｄ74 항체 및 그 이용방법
EP1500402A4 (en) 2002-04-26 2009-12-30 Takeda Pharmaceutical INHIBITOR OF CELL DEATH
US20050208010A1 (en) * 2002-07-10 2005-09-22 L'oreal Genes from Chromosome 3, 5 and 11 involved in premature canities
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
US20050202010A1 (en) * 2003-08-29 2005-09-15 Giroir Brett P. Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
WO2006102191A1 (en) 2005-03-24 2006-09-28 Avanir Pharmaceuticals Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
WO2007044622A1 (en) 2005-10-07 2007-04-19 Yale University Use of mif and mif pathway agonists
US9238689B2 (en) 2011-07-15 2016-01-19 Morpho Sys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
CA2842195A1 (en) 2011-07-18 2013-01-24 Immunomedics, Inc. Fty720 increases cd74 expression and sensitizes cancer cells to anti-cd74 antibody-mediated cell death
AU2012320597C1 (en) 2011-10-07 2015-10-15 Baxalta GmbH oxMIF as a diagnostic marker
CN104994875B (zh) 2013-02-15 2018-10-09 免疫医疗公司 嵌合和人源化抗组蛋白抗体
WO2015051330A1 (en) 2013-10-03 2015-04-09 Oregon Health & Science University RECOMBINANT POLYPEPTIDES COMPRISING MHC CLASS II α1 DOMAINS
EP2944310B1 (en) 2014-05-16 2018-03-21 Mifcare MIF inhibitors for the acute or chronic treatment of pulmonary hypertension
US10351621B2 (en) 2014-06-24 2019-07-16 Immunomedics, Inc. Anti-histone therapy in acute kidney injury
US9580495B2 (en) 2014-06-24 2017-02-28 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
WO2016057702A2 (en) 2014-10-07 2016-04-14 Cornell University Methods for prognosing and preventing metastatic liver disease
US10525101B2 (en) 2015-10-23 2020-01-07 Oregon Health & Science University Methods of treating inflammatory or autoimmune disorders with compounds that bind macrophage migration inhibitory factor
CA3044082A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
CN114668832A (zh) * 2022-04-27 2022-06-28 西安市第一医院 Mif及其受体cd74制备调控细胞功能和分裂增殖药物中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02124759A (ja) * 1988-07-15 1990-05-14 Sumitomo Electric Ind Ltd 超電導材料の製造方法
WO1990011301A1 (en) * 1989-03-17 1990-10-04 Genetics Institute, Inc. Human macrophage migration inhibitory factor
US6774227B1 (en) * 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
US6645493B1 (en) * 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
WO1994026307A1 (en) * 1993-05-17 1994-11-24 The Picower Institute For Medical Research Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity
US5559028A (en) * 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting
US5586694A (en) 1994-12-14 1996-12-24 Fragrance Systems International, Inc. Perfume applicator with replaceable cartridges
WO1997025344A1 (en) * 1996-01-03 1997-07-17 The Australian National University Clip analogues and autoimmune disease
US6492428B1 (en) * 2000-07-26 2002-12-10 The Picower Institute For Medical Research Compounds having MIF antagonist activity
US6420188B1 (en) * 1996-02-16 2002-07-16 The Picower Institute For Medical Research Screening assay for the identification of inhibitors for macrophage migration inhibitory factor
US5726020A (en) * 1996-06-11 1998-03-10 University Of Massachusetts Inhibition of II synthesis
WO1998037178A1 (en) * 1997-02-24 1998-08-27 The Johns Hopkins University Immunomodulatory polypeptides derived from the invariant chain of mhc class ii
ATE302217T1 (de) * 1997-05-02 2005-09-15 Us Gov Health & Human Serv Immuntoxine, die ein onc protein enthalten, gegen bösartige zellen
CA2205680A1 (en) * 1997-05-16 1998-11-16 The University Of Western Ontario Clip immunomodulatory peptide
DE60042785D1 (de) * 1999-06-09 2009-10-01 Immunomedics Inc Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
CA2389229A1 (en) * 1999-10-29 2001-05-10 The Picower Institute For Medical Research Compounds having mif antagonist activity
JP4202763B2 (ja) * 2001-03-29 2008-12-24 サイトカイン・ファーマサイエンシズ・インコーポレーテッド マクロファージ遊走阻止因子レセプターとしてのｍｈｃクラスｉｉ不変鎖ポリペプチド使用のための方法及び組成物
UY27304A1 (es) * 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
US9540322B2 (en) * 2008-08-18 2017-01-10 Yale University MIF modulators
US9643922B2 (en) * 2008-08-18 2017-05-09 Yale University MIF modulators

Similar Documents

Publication Publication Date Title
Qing et al. Nephritogenic anti‐DNA antibodies regulate gene expression in MRL/lpr mouse glomerular mesangial cells
JP2006502416A5 (enExample)
Berrih‐Aknin et al. CCL21 overexpressed on lymphatic vessels drives thymic hyperplasia in myasthenia
JP2010516678A (ja) Ｔｒｅｍ−１による炎症治療、検出およびモニタリング
JP2002542157A5 (enExample)
WO2008076868A2 (en) Methods and compositions related to modulation of receptor tyrosine kinase orphan receptor-1 (ror-1)
CA2365898A1 (en) Ibd-associated microbial antigens and methods of using same
CA2133306A1 (en) Amplification of human mdm2 gene in human tumors
JP2007510664A5 (enExample)
JP2011507810A5 (enExample)
JP2009039107A5 (enExample)
US20130236531A1 (en) Pharmaceutical composition including an hif-2 alpha inhibitor as an active ingredient for preventing or treating arthritis
Dambinova et al. The presence of autoantibodies to N-terminus domain of GluR1 subunit of AMPA receptor in the blood serum of patients with epilepsy
JP2019531716A5 (enExample)
Han et al. IFN-inducible protein-10 has a differential role in podocyte during Thy 1.1 glomerulonephritis
EP2210112B1 (en) Diagnostic methods for hiv infection
JP2014518624A5 (enExample)
JP2004513614A5 (enExample)
He et al. The current status of anti-citrullinated protein antibodies and citrullinated protein-reactive B cells in the pathogenesis of rheumatoid arthritis
JP2005507648A5 (enExample)
KR101098186B1 (ko) 피에이유에프(ｐａｕｆ) 특이적인 인간 단일클론항체, 이를 포함하는 암 치료용 조성물, 이를 이용하는 암의 진단방법
JPH1066585A5 (enExample)
JP2003527844A5 (enExample)
JP2003510078A5 (enExample)
Wyers et al. Immunological cross-reactions and interactions between the Drosophila melanogaster ref (2) P protein and sigma rhabdovirus proteins